Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen

被引：0
|
作者：
Aleksi Tornio
Mikko Niemi
Pertti J. Neuvonen
Janne T. Backman
机构：
[1] University of Helsinki,Department of Clinical Pharmacology
来源：
European Journal of Clinical Pharmacology | 2007年 / 63卷
关键词：
CYP2C8; Drug interaction; Gemfibrozil; Ibuprofen enantiomers; Stereoselectivity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：463 / 469
页数：6
相关论文
共 50 条
  • [31] Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms
    Yasar, U
    Lundgren, S
    Eliasson, E
    Bennet, A
    Wiman, B
    de Faire, U
    Rane, A
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 299 (01) : 25 - 28
  • [32] Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide
    Kajosaari, LI
    Jaakkola, T
    Neuvonen, PJ
    Backman, JT
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (03) : 217 - 223
  • [33] Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide
    Lauri I. Kajosaari
    Tiina Jaakkola
    Pertti J. Neuvonen
    Janne T. Backman
    European Journal of Clinical Pharmacology, 2006, 62 : 217 - 223
  • [34] Influence of CYP2C8☆13 and CYP2C8☆14 Alleles on Amiodarone N-Deethylation
    Hanioka, Nobumitsu
    Matsumoto, Kimiaki
    Saito, Yoshiro
    Narimatsu, Shizuo
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 108 (05) : 359 - 362
  • [35] Evaluation of CYP2C8 Inhibition In Vitro: Utility of Montelukast as a Selective CYP2C8 Probe Substrate
    VandenBrink, Brooke M.
    Foti, Robert S.
    Rock, Dan A.
    Wienkers, Larry C.
    Wahlstrom, Jan L.
    DRUG METABOLISM AND DISPOSITION, 2011, 39 (09) : 1546 - 1554
  • [36] Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro:: Potential for interactions with CYP2C8 inhibitors
    Jaakkola, Tiina
    Laitila, Jouko
    Neuvonen, Pertti J.
    Backman, Janne T.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2006, 99 (01) : 44 - 51
  • [37] Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro
    Yu, Lushan
    Shi, Da
    Ma, Liping
    Zhou, Quan
    Zeng, Su
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2013, 34 (05) : 278 - 287
  • [38] THE PAN-PHOSPHOINOSITIDE-3 KINASE INHIBITOR PICTILISIB (GDC-0941), AN IN VITRO CYP2C8 INHIBITOR, DOES NOT IMPACT THE PHARMACOKINETICS OF PACLITAXEL, A CYP2C8 SUBSTRATE.
    Morrissey, K.
    Lu, T.
    Faber, K.
    Apt, D.
    Lauchle, J.
    Schutzman, J.
    Shankar, G.
    Singel, S.
    Dresser, M.
    Jin, J.
    Ware, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S78 - S79
  • [39] CYP2C8 polymorphism among the Portuguese
    Cavaco, I
    Piedade, R
    Gil, JP
    Ribeiro, V
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2006, 44 (02) : 168 - 170
  • [40] Studies to Further Investigate the Inhibition of Human Liver Microsomal CYP2C8 by the Acyl-β-Glucuronide of Gemfibrozil
    Jenkins, S. M.
    Zvyaga, T.
    Johnson, S. R.
    Hurley, J.
    Wagner, A.
    Burrell, R.
    Turley, W.
    Leet, J. E.
    Philip, T.
    Rodrigues, A. D.
    DRUG METABOLISM AND DISPOSITION, 2011, 39 (12) : 2421 - 2430
12345